FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4213440518> ?p ?o ?g. }

• W4213440518 endingPage "112" @default.
• W4213440518 startingPage "97" @default.
• W4213440518 abstract "Backgroundβ-adrenergic receptors are upregulated in melanoma cells and contribute to an immunosuppressive, pro-tumorigenic microenvironment. This study investigated the prognostic and predictive value of β-adrenoreceptor blockade by β-blockers in the EORTC1325/KEYNOTE-054 randomised controlled trial.MethodsPatients with resected stage IIIA, IIIB or IIIC melanoma and regional lymphadenectomy received 200 mg of adjuvant pembrolizumab (n = 514) or placebo (n = 505) every three weeks for one year or until recurrence or unacceptable toxicity. At a median follow-up of 3 years, pembrolizumab prolonged recurrence-free survival (RFS) compared to placebo (hazard ratio (HR) 0.56, 95% confidence interval (CI) 0.47–0.68). β-blocker use was defined as oral administration of any β-blocker within 30 days of randomisation. A multivariable Cox proportional hazard model was used to estimate the HR for the association between the use of β-blockers and RFS.ResultsNinety-nine (10%) of 1019 randomised patients used β-blockers at baseline. β-blockers had no independent prognostic effect on RFS: HR 0.96 (95% CI 0.70–1.31). The HRs of RFS associated with β-blocker use were 0.67 (95% CI 0.38–1.19) in the pembrolizumab arm and 1.15 (95% CI 0.80–1.66) in the placebo arm. The HR of RFS associated with pembrolizumab compared to placebo was 0.34 (95% CI 0.18–0.65) among β-blocker users and 0.59 (95% CI 0.48–0.71) among those not using β-blockers.ConclusionsThis study suggests no prognostic effect of β-blockers in resected high-risk stage III melanoma. However, β-blockers may predict improved efficacy of adjuvant pembrolizumab treatment. The combination of immunotherapy with β-blockers merits further investigation.This study is registered with ClinicalTrials.gov, NCT02362594, and EudraCT, 2014-004944-37." @default.
• W4213440518 created "2022-02-25" @default.
• W4213440518 creator A5001568438 @default.
• W4213440518 creator A5004262252 @default.
• W4213440518 creator A5004497401 @default.
• W4213440518 creator A5010492722 @default.
• W4213440518 creator A5015077519 @default.
• W4213440518 creator A5015081105 @default.
• W4213440518 creator A5016161312 @default.
• W4213440518 creator A5019573174 @default.
• W4213440518 creator A5020064368 @default.
• W4213440518 creator A5029398339 @default.
• W4213440518 creator A5033330872 @default.
• W4213440518 creator A5034365278 @default.
• W4213440518 creator A5047916486 @default.
• W4213440518 creator A5052579165 @default.
• W4213440518 creator A5054723003 @default.
• W4213440518 creator A5056132643 @default.
• W4213440518 creator A5057991836 @default.
• W4213440518 creator A5058080268 @default.
• W4213440518 creator A5061072132 @default.
• W4213440518 creator A5064026461 @default.
• W4213440518 creator A5069095893 @default.
• W4213440518 creator A5071577704 @default.
• W4213440518 creator A5073133195 @default.
• W4213440518 creator A5076054848 @default.
• W4213440518 creator A5077991404 @default.
• W4213440518 creator A5079760997 @default.
• W4213440518 creator A5079852624 @default.
• W4213440518 creator A5083061830 @default.
• W4213440518 creator A5088390068 @default.
• W4213440518 creator A5089182718 @default.
• W4213440518 creator A5090545021 @default.
• W4213440518 date "2022-04-01" @default.
• W4213440518 modified "2023-10-15" @default.
• W4213440518 title "Prognostic and predictive value of β-blockers in the EORTC 1325/KEYNOTE-054 phase III trial of pembrolizumab versus placebo in resected high-risk stage III melanoma" @default.
• W4213440518 cites W1510924163 @default.
• W4213440518 cites W1965617397 @default.
• W4213440518 cites W1974008746 @default.
• W4213440518 cites W2014821959 @default.
• W4213440518 cites W2034948055 @default.
• W4213440518 cites W2035072407 @default.
• W4213440518 cites W2087352349 @default.
• W4213440518 cites W2141382054 @default.
• W4213440518 cites W2170674837 @default.
• W4213440518 cites W2171415105 @default.
• W4213440518 cites W2748524892 @default.
• W4213440518 cites W2760246662 @default.
• W4213440518 cites W2768592202 @default.
• W4213440518 cites W2785918956 @default.
• W4213440518 cites W2786396800 @default.
• W4213440518 cites W2797309423 @default.
• W4213440518 cites W2803072667 @default.
• W4213440518 cites W2957658998 @default.
• W4213440518 cites W2980715209 @default.
• W4213440518 cites W3011435761 @default.
• W4213440518 cites W3025905835 @default.
• W4213440518 cites W3087401339 @default.
• W4213440518 cites W3097090532 @default.
• W4213440518 cites W3099516709 @default.
• W4213440518 cites W3153228158 @default.
• W4213440518 doi "https://doi.org/10.1016/j.ejca.2022.01.017" @default.
• W4213440518 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35220182" @default.
• W4213440518 hasPublicationYear "2022" @default.
• W4213440518 type Work @default.
• W4213440518 citedByCount "10" @default.
• W4213440518 countsByYear W42134405182022 @default.
• W4213440518 countsByYear W42134405182023 @default.
• W4213440518 crossrefType "journal-article" @default.
• W4213440518 hasAuthorship W4213440518A5001568438 @default.
• W4213440518 hasAuthorship W4213440518A5004262252 @default.
• W4213440518 hasAuthorship W4213440518A5004497401 @default.
• W4213440518 hasAuthorship W4213440518A5010492722 @default.
• W4213440518 hasAuthorship W4213440518A5015077519 @default.
• W4213440518 hasAuthorship W4213440518A5015081105 @default.
• W4213440518 hasAuthorship W4213440518A5016161312 @default.
• W4213440518 hasAuthorship W4213440518A5019573174 @default.
• W4213440518 hasAuthorship W4213440518A5020064368 @default.
• W4213440518 hasAuthorship W4213440518A5029398339 @default.
• W4213440518 hasAuthorship W4213440518A5033330872 @default.
• W4213440518 hasAuthorship W4213440518A5034365278 @default.
• W4213440518 hasAuthorship W4213440518A5047916486 @default.
• W4213440518 hasAuthorship W4213440518A5052579165 @default.
• W4213440518 hasAuthorship W4213440518A5054723003 @default.
• W4213440518 hasAuthorship W4213440518A5056132643 @default.
• W4213440518 hasAuthorship W4213440518A5057991836 @default.
• W4213440518 hasAuthorship W4213440518A5058080268 @default.
• W4213440518 hasAuthorship W4213440518A5061072132 @default.
• W4213440518 hasAuthorship W4213440518A5064026461 @default.
• W4213440518 hasAuthorship W4213440518A5069095893 @default.
• W4213440518 hasAuthorship W4213440518A5071577704 @default.
• W4213440518 hasAuthorship W4213440518A5073133195 @default.
• W4213440518 hasAuthorship W4213440518A5076054848 @default.
• W4213440518 hasAuthorship W4213440518A5077991404 @default.
• W4213440518 hasAuthorship W4213440518A5079760997 @default.
• W4213440518 hasAuthorship W4213440518A5079852624 @default.
• W4213440518 hasAuthorship W4213440518A5083061830 @default.
• W4213440518 hasAuthorship W4213440518A5088390068 @default.

• next